Product
Unadjuvanted Panblok
1 clinical trial
2 indications
Indication
InfluenzaIndication
Healthy Control ParticipantsClinical trial
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and OlderStatus: Completed, Estimated PCD: 2023-02-18